Opens in a new tab

Promosome v BioNTech (CFI, 10 March 2025)

Date10 March 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionApplication RoP262A
Registry referenceApp_15/2025 · ORD_6596/2025
PartiesBioNTech Innovative Manufacturing Services GmbH , Pfizer Manufacturing Belgium NV , Pfizer SAS, BioNTech Manufacturing GmbH , Pfizer AB , B…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 10 March 2025 (UPC_CFI_846/2024, ACT_68533/2024, ORD_6596/2025), the judge-rapporteur of the Munich Local Division (A. Kupecz) largely granted the application of Promosome, claimant in an infringement action on EP 2 401 365 against five BioNTech group companies and four Pfizer group companies, for protection of a licence agreement and its amendment filed as exhibits. The order defines the circle of persons admitted to confidential information under Rule 262A.

Question

Which persons on the defendants’ side may access the confidential information, and should the Court order its return or destruction at the end of the proceedings?

Decision

The exhibits are treated as confidential, the defendants contesting neither the principle nor the scope of protection. Access may be restricted where the applicant’s grounds clearly outweigh the other party’s interest, with no more persons than necessary and at least one natural person per party together with its representatives (Rule 262A.5 and 6). Rule 262A.6 does not require the person admitted to be an employee or an Art. 48 representative, access extends to team members actively involved, lawyers, patent attorneys and support staff, under the representative’s personal responsibility. The confidentiality obligation survives the proceedings, and a penalty payment may sanction a culpable breach. The request for return or destruction is rejected for lack of legal basis and separate interest. So is the request concerning Court staff, to whom Rule 262A does not apply.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 10, 45, 48 and 58
Rules of Procedure
Rules 102.2, 262.2, 262A and 333
Case law cited
Daedalus Prime v Xiaomi, Court of Appeal, 12 February 2025, Amazon v Nokia, Court of Appeal, 20 January 2025, Sanofi v Accord, Munich Local Division, 14 January 2025, Munich Local Division, 2 December 2024 (unpublished order)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262A
Outcome (Dhenne Avocats summary)
Le contrat de licence produit par Promosome est classé confidentiel. L'accès est limité aux représentants des défenderesses, à leurs équipes activement impliquées et à des personnes physiques désignées, sans obligation de restitution en fin d'instance.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 401 365
Reengineering mrna primary structure for enhanced protein production
recorded proprietor: Scripps Research Institute
Mentioned in the analysis (role not qualified)
Also mentioned in 6 other decision(s): Promosome v BioNTech (CFI, UPC_CFI_846/2024, 7 July 2026) · Promosome v BioNTech (CFI, 15 July 2025) · Promosome v BioNTech (CFI, 17 April 2025) · Promosome v BioNTech (CFI, 9 April 2025) · Promosome v BioNTech (CFI, 3 April 2025) · Promosome v BioNTech (CoA, 12 October 2026)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.